Celgene nabs FDA approval for blockbuster hopeful anemia med Reblozyl
Bristol-Myers Squibb’s $74 billion pending pick-up of Celgene has notched a win already with an FDA approval for JAK med Inrebic. Now the consummation has grabbed another victory with an approval for a Celgene blood disease candidate––and it could spell blockbuster sales ahead.
Source: Fierce Pharma
Celgene nabs FDA approval for blockbuster hopeful anemia med Reblozyl
